

HR 3812

REMEDY Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 17, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jul 18, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3812>

Sponsor

Name: Rep. McKinley, David B. [R-WV-1]

Party: Republican • **State:** WV • **Chamber:** House

Cosponsors (1 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jul 17, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jul 18, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 1209	Identical bill	Apr 11, 2019: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 17, 2019)

Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act

This bill addresses drug patents with respect to Food and Drug Administration (FDA) approval of a drug application.

Currently, when the owner of a brand-name drug approval sues a generic drug company for patent infringement based on the generic company's application for FDA approval of a generic version of the brand-name drug, there is generally a 30-month stay on the approval of the generic version. Under this bill, the stay goes into effect only if the lawsuit alleges infringement of a patent that claims the drug compound.

When the U.S. Patent and Trademark Office invalidates a patent for a drug, the FDA must update its list of relevant patents for the drug.

Actions Timeline

- **Jul 18, 2019:** Referred to the Subcommittee on Health.
- **Jul 17, 2019:** Introduced in House
- **Jul 17, 2019:** Referred to the House Committee on Energy and Commerce.